No retraction, correction or concern found when last checked on Oct 17, 2026.

Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets

Shaosen Zhang, Xinyi Xiao, Yonglin Yi and 5 more

Signal Transduction and Targeted Therapy · 2024 · Review · CC BY

Abstract

Tumorigenesis is a multistep process, with oncogenic mutations in a normal cell conferring clonal advantage as the initial event. However, despite pervasive somatic mutations and clonal expansion in normal tissues, their transformation into cancer remains a rare event, indicating the presence of additional driver events for progression to an irreversible, highly heterogeneous, and invasive lesion. Recently, researchers are emphasizing the mechanisms of environmental tumor risk factors and epigenetic alterations that are profoundly influencing early clonal expansion and malignant evolution, independently of inducing mutations. Additionally, clonal evolution in tumorigenesis reflects a multifaceted interplay between cell-intrinsic identities and various cell-extrinsic factors that exert selective pressures to either restrain uncontrolled proliferation or allow specific clones to progress into tumors. However, the mechanisms by which driver events induce both intrinsic cellular competency and remodel environmental stress to facilitate malignant transformation are not fully understood. In this review, we summarize the genetic, epigenetic, and external driver events, and their effects on the co-evolution of the transformed cells and their ecosystem during tumor initiation and early malignant evolution. A deeper understanding of the earliest molecular events holds promise for translational applications, predicting individuals at high-risk of tumor and developing strategies to intercept malignant transformation.

References 533

1.
A New, Quantitative, Approach to the Study of the Stages of Chemical Carcinogenesis in the Mouse's Skin · 1947
No notice
2.
Cancer as a disease of old age: changing mutational and microenvironmental landscapes · 2020
No notice
3.
Kakiuchi N, Ogawa S. Clonal expansion in non-cancer tissues. Nat. Rev. Cancer. 2021;21:239-256.
Not in our library10.1038/s41568-021-00335-3
4.
Crosby D, et al. Early detection of cancer. Science. 2022;375:eaay9040.
Not in our library10.1126/science.aay9040
5.
Martin GS. The road to Src. Oncogene. 2004;23:7910-7917.
Not in our library10.1038/sj.onc.1208077
6.
Boveri T. The Origin of Malignant Tumors. Arch. Intern. Med. 1929;44:910.
Not in our library10.1001/archinte.1929.00140060125019
7.
A New Theory on the Cancer-inducing Mechanism · 1953
No notice
8.
Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br. J. Cancer. 2004;91:1983-1989.
Not in our library10.1038/sj.bjc.6602297
9.
Huebner RJ, Todaro GJ. Oncogenes of RNA tumor viruses as determinants of cancer. Proc. Natl Acad. Sci. USA. 1969;64:1087-1094.
Not in our library10.1073/pnas.64.3.1087
10.
Weiss R. Molecular analysis of the oncogene. Nature. 1976;260:93-93.
Not in our library10.1038/260093a0
11.
Klein G, Klein E. Evolution of tumours and the impact of molecular oncology. Nature. 1985;315:190-195.
Not in our library10.1038/315190a0
12.
Parada LF, Tabin CJ, Shih C, Weinberg RA. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature. 1982;297:474-478.
Not in our library10.1038/297474a0
13.
Santos E, et al. T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB-and Harvey-MSV transforming genes. Nature. 1982;298:343-347.
Not in our library10.1038/298343a0
14.
Martínez-Jiménez F, et al. A compendium of mutational cancer driver genes. Nat. Rev. Cancer. 2020;20:555-572.
Not in our library10.1038/s41568-020-0290-x
15.
Hudson TJ, et al. International network of cancer genome projects. Nature. 2010;464:993-998.
Not in our library10.1038/nature08987
16.
Pan-cancer analysis of whole genomes · 2020
Corrected
17.
Greenman C, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446:153-158.
Not in our library10.1038/nature05610
18.
Dressler L, et al. Comparative assessment of genes driving cancer and somatic evolution in non-cancer tissues: an update of the Network of Cancer Genes (NCG) resource. Genome Biol. 2022;23:35.
Not in our library10.1186/s13059-022-02607-z
19.
Fowler JC, Jones PH. Somatic mutation: What shapes the mutational landscape of normal epithelia? Cancer Discov. 2022;12:1642-1655.
Not in our library10.1158/2159-8290.cd-22-0145
20.
Triolo VA. Nineteenth century foundations of cancer research advances in tumor pathology, nomenclature, and theories of oncogenesis. Cancer Res. 1965;25:75-106.
Not in our library
21.
Watanabe T, Dewey MJ, Mintz B. Teratocarcinoma cells as vehicles for introducing specific mutant mitochondrial genes into mice. Proc. Natl. Acad. Sci. USA. 1978;75:5113-5117,.
Not in our library10.1073/pnas.75.10.5113
22.
Dolberg DS, Hollingsworth R, Hertle M, Bissell MJ. Wounding and its role in RSV-mediated tumor formation. Science. 1985;230:676-678,.
Not in our library10.1126/science.2996144
23.
Sieweke MH, Thompson NL, Sporn MB, Bissell MJ. Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta. Science. 1990;248:1656-1660,.
Not in our library10.1126/science.2163544
24.
Barcellos-Hoff MH, Ravani SA. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 2000;60:1254-1260,.
Not in our library
25.
Maffini MV, et al. The stroma as a crucial target in rat mammary gland carcinogenesis. J. Cell Sci. 2004;117:1495-1502.
Not in our library10.1242/jcs.01000
26.
Soto AM, Sonnenschein C. The tissue organization field theory of cancer: A testable replacement for the somatic mutation theory. Bioessays. 2011;33:332-340.
Not in our library10.1002/bies.201100025
27.
Rozenblatt-Rosen O, et al. The human tumor atlas network: charting tumor transitions across space and time at single-cell resolution. Cell. 2020;181:236-249.
Not in our library10.1016/j.cell.2020.03.053
28.
Epigenetic regulation during cancer transitions across 11 tumour types · 2023
No notice
29.
Liang WW, et al. Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin. Cancer Cell. 2023;41:1567-1585.e1567.
Not in our library10.1016/j.ccell.2023.07.013
30.
Li Y, et al. Pan-cancer proteogenomics connects oncogenic drivers to functional states. Cell. 2023;186:3921-3944.e3925.
Not in our library10.1016/j.cell.2023.07.014
31.
Geffen Y, et al. Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation. Cell. 2023;186:3945-3967.e3926.
Not in our library10.1016/j.cell.2023.07.013
32.
Kinker GS, et al. Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity. Nat. Genet. 2020;52:1208-1218.
Not in our library10.1038/s41588-020-00726-6
33.
Barkley D, et al. Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment. Nat. Genet. 2022;54:1192-1201.
Not in our library10.1038/s41588-022-01141-9
34.
Gavish A, et al. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature. 2023;618:598-606.
Not in our library10.1038/s41586-023-06130-4
35.
Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-421.
Not in our library10.1038/nature12477
36.
Mustjoki S, Young NS. Somatic mutations in “Benign” disease. N. Engl. J. Med. 2021;384:2039-2052.
Not in our library10.1056/nejmra2101920
37.
Li R, et al. A body map of somatic mutagenesis in morphologically normal human tissues. Nature. 2021;597:398-403.
Not in our library10.1038/s41586-021-03836-1
38.
Moore L, et al. The mutational landscape of human somatic and germline cells. Nature. 2021;597:381-386.
Not in our library10.1038/s41586-021-03822-7
39.
Li R, et al. Macroscopic somatic clonal expansion in morphologically normal human urothelium. Science. 2020;370:82-89.
Not in our library10.1126/science.aba7300
40.
Yizhak K, et al. RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues. Science. 2019;364:eaaw0726.
Not in our library10.1126/science.aaw0726
41.
Colom B, et al. Mutant clones in normal epithelium outcompete and eliminate emerging tumours. Nature. 2021;598:510-514.
Not in our library10.1038/s41586-021-03965-7
42.
Chang J, et al. Genomic alterations driving precancerous to cancerous lesions in esophageal cancer development. Cancer Cell. 2023;41:2038-2050.e2035.
Not in our library10.1016/j.ccell.2023.11.003
43.
Ordered and deterministic cancer genome evolution after p53 loss · 2022
No notice
44.
Murai K, et al. p53 mutation in normal esophagus promotes multiple stages of carcinogenesis but is constrained by clonal competition. Nat. Commun. 2022;13:6206.
Not in our library10.1038/s41467-022-33945-y
45.
Taylor AM, et al. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell. 2018;33:676-689.e673.
Not in our library10.1016/j.ccell.2018.03.007
46.
Drews RM, et al. A pan-cancer compendium of chromosomal instability. Nature. 2022;606:976-983.
Not in our library10.1038/s41586-022-04789-9
47.
Krupina K, Goginashvili A, Cleveland DW. Scrambling the genome in cancer: Causes and consequences of complex chromosome rearrangements. Nat. Rev. Genet. 2024;25:196-210.
Not in our library10.1038/s41576-023-00663-0
48.
Zhu J, Tsai HJ, Gordon MR, Li R. Cellular stress associated with aneuploidy. Dev. Cell. 2018;44:420-431.
Not in our library10.1016/j.devcel.2018.02.002
49.
The evolutionary history of 2,658 cancers · 2020
Corrected
50.
Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development · 2011
No notice
51.
Rausch T, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 2012;148:59-71.
Not in our library10.1016/j.cell.2011.12.013
52.
Martincorena I, et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science. 2015;348:880-886.
Not in our library10.1126/science.aaa6806
53.
Wijewardhane N, Dressler L, Ciccarelli FD. Normal somatic mutations in cancer transformation. Cancer Cell. 2021;39:125-129.
Not in our library10.1016/j.ccell.2020.11.002
54.
Yokoyama A, et al. Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature. 2019;565:312-317.
Not in our library10.1038/s41586-018-0811-x
55.
Lawson ARJ, et al. Extensive heterogeneity in somatic mutation and selection in the human bladder. Science. 2020;370:75-82.
Not in our library10.1126/science.aba8347
56.
Weaver JMJ, et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat. Genet. 2014;46:837-843.
Not in our library10.1038/ng.3013
57.
Shain AH, et al. The genetic evolution of melanoma from precursor lesions. N. Engl. J. Med. 2015;373:1926-1936.
Not in our library10.1056/nejmoa1502583
58.
Choi CR, Bakir IA, Hart AL, Graham TA. Clonal evolution of colorectal cancer in IBD. Nat. Rev. Gastroenterol. Hepatol. 2017;14:218-229.
Not in our library10.1038/nrgastro.2017.1
59.
Stachler MD, et al. Detection of mutations in Barrett’s esophagus before progression to high-grade dysplasia or adenocarcinoma. Gastroenterology. 2018;155:156-167.
Not in our library10.1053/j.gastro.2018.03.047
60.
Evolutionary history of human colitis-associated colorectal cancer · 2018
No notice
61.
Kader T, et al. Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. J. Pathol. 2019;248:326-338.
Not in our library10.1002/path.5262
62.
Deciphering cell lineage specification of human lung adenocarcinoma with single-cell RNA sequencing · 2021
No notice
63.
Huang KK, et al. Genomic and epigenomic profiling of high-risk intestinal metaplasia reveals molecular determinants of progression to gastric cancer. Cancer Cell. 2018;33:137-150.e135.
Not in our library10.1016/j.ccell.2017.11.018
64.
Baker TM, Waise S, Tarabichi M, Van Loo P. Aneuploidy and complex genomic rearrangements in cancer evolution. Nat. Cancer. 2024;5:228-239.
Not in our library10.1038/s43018-023-00711-y
65.
Extrachromosomal DNA in the cancerous transformation of Barrett’s oesophagus · 2023
No notice
66.
Watkins TBK, et al. Pervasive chromosomal instability and karyotype order in tumour evolution. Nature. 2020;587:126-132.
Not in our library10.1038/s41586-020-2698-6
67.
Minussi DC, et al. Breast tumours maintain a reservoir of subclonal diversity during expansion. Nature. 2021;592:302-308.
Not in our library10.1038/s41586-021-03357-x
68.
Gao R, et al. Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nat. Biotechnol. 2021;39:599-608.
Not in our library10.1038/s41587-020-00795-2
69.
Zaccaria S, Raphael BJ. Characterizing allele- and haplotype-specific copy numbers in single cells with CHISEL. Nat. Biotechnol. 2021;39:207-214.
Not in our library10.1038/s41587-020-0661-6
70.
Signatures of copy number alterations in human cancer · 2022
No notice
71.
Ratushny V, et al. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J. Clin. Invest. 2012;122:464-472.
Not in our library10.1172/jci57415
72.
Tufaro AP, et al. Molecular markers in cutaneous squamous cell carcinoma. Int. J. Surg. Oncol. 2011;2011:231475.
Not in our library10.1155/2011/231475
73.
Lee JJ, et al. Tracing oncogene rearrangements in the mutational history of lung adenocarcinoma. Cell. 2019;177:1842-1857.e1821.
Not in our library10.1016/j.cell.2019.05.013
74.
Wu S, et al. Circular ecDNA promotes accessible chromatin and high oncogene expression. Nature. 2019;575:699-703.
Not in our library10.1038/s41586-019-1763-5
75.
Hung KL, et al. ecDNA hubs drive cooperative intermolecular oncogene expression. Nature. 2021;600:731-736.
Not in our library10.1038/s41586-021-04116-8
76.
Ben-David U, Amon A. Context is everything: aneuploidy in cancer. Nat. Rev. Genet. 2020;21:44-62.
Not in our library10.1038/s41576-019-0171-x
77.
Vasudevan A, et al. Aneuploidy as a promoter and suppressor of malignant growth. Nat. Rev. Cancer. 2021;21:89-103.
Not in our library10.1038/s41568-020-00321-1
78.
López S, et al. Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution. Nat. Genet. 2020;52:283-293.
Not in our library10.1038/s41588-020-0584-7
79.
Bielski CM, et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat. Genet. 2018;50:1189-1195.
Not in our library10.1038/s41588-018-0165-1
80.
Kim JE, et al. High prevalence of TP53 loss and whole-genome doubling in early-onset colorectal cancer. Exp. Mol. Med. 2021;53:446-456.
Not in our library10.1038/s12276-021-00583-1
81.
Mackenzie KJ, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature. 2017;548:461-465.
Not in our library10.1038/nature23449
82.
Bakhoum SF, Cantley LC. The multifaceted role of chromosomal instability in cancer and its microenvironment. Cell. 2018;174:1347-1360.
Not in our library10.1016/j.cell.2018.08.027
83.
Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat. Rev. Genet. 2018;19:371-384.
Not in our library10.1038/s41576-018-0004-3
84.
Booth LN, Brunet A. The aging epigenome. Mol. Cell. 2016;62:728-744,.
Not in our library10.1016/j.molcel.2016.05.013
85.
Widschwendter M, et al. Epigenome-based cancer risk prediction: rationale, opportunities and challenges. Nat. Rev. Clin. Oncol. 2018;15:292-309.
Not in our library10.1038/nrclinonc.2018.30
86.
Accumulation of genetic and epigenetic alterations in normal cells and cancer risk · 2019
No notice
87.
Feinberg AP, Tycko B. The history of cancer epigenetics. Nat. Rev. Cancer. 2004;4:143-153.
Not in our library10.1038/nrc1279
88.
Hu X, et al. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nat. Commun. 2021;12:687.
Not in our library10.1038/s41467-021-20907-z
89.
Methylation profiling identifies two subclasses of squamous cell carcinoma related to distinct cells of origin · 2018
Not checked
90.
Luo Y, et al. Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer. Gastroenterology. 2014;147:418-429.e418.
Not in our library10.1053/j.gastro.2014.04.039
91.
Mack SC, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature. 2014;506:445-450.
Not in our library10.1038/nature13108
92.
Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum. Mol. Genet. 2007;16:R50-R59.
Not in our library10.1093/hmg/ddm018
93.
Macrae TA, Fothergill-Robinson J, Ramalho-Santos M. Regulation, functions and transmission of bivalent chromatin during mammalian development. Nat. Rev. Mol. Cell. Biol. 2023;24:6-26.
Not in our library10.1038/s41580-022-00518-2
94.
Teschendorff AE, et al. The multi-omic landscape of transcription factor inactivation in cancer. Genome Med. 2016;8:89.
Not in our library10.1186/s13073-016-0342-8
95.
Liu T, et al. Computational identification of preneoplastic cells displaying high stemness and risk of cancer progression. Cancer Res. 2022;82:2520-2537.
Not in our library10.1158/0008-5472.can-22-0668
96.
Yang L, et al. DNMT3A loss drives enhancer hypomethylation in FLT3-ITD-associated leukemias. Cancer Cell. 2016;29:922-934.
Not in our library10.1016/j.ccell.2016.05.003
97.
Lu R, et al. Epigenetic perturbations by Arg882-mutated DNMT3A potentiate aberrant stem cell gene-expression program and acute leukemia development. Cancer Cell. 2016;30:92-107.
Not in our library10.1016/j.ccell.2016.05.008
98.
Langille E, et al. Loss of epigenetic regulation disrupts lineage integrity, induces aberrant alveogenesis, and promotes breast cancer. Cancer Discov. 2022;12:2930-2953.
Not in our library10.1158/2159-8290.cd-21-0865
99.
Alam H, et al. KMT2D deficiency impairs super-enhancers to confer a glycolytic vulnerability in lung cancer. Cancer Cell. 2020;37:599-617.e597.
Not in our library10.1016/j.ccell.2020.03.005
100.
Pan Y, et al. KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition. Cancer Cell. 2023;41:88-105.e108.
Not in our library10.1016/j.ccell.2022.11.015
101.
Flavahan WA, et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature. 2016;529:110-114.
Not in our library10.1038/nature16490
102.
Klutstein M, Nejman D, Greenfield R, Cedar H. DNA methylation in cancer and aging. Cancer Res. 2016;76:3446-3450.
Not in our library10.1158/0008-5472.can-15-3278
103.
Vicente-Dueñas C, et al. Epigenetic priming in cancer initiation. Trends Cancer. 2018;4:408-417.
Not in our library10.1016/j.trecan.2018.04.007
104.
Genovese G, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 2014;371:2477-2487.
Not in our library10.1056/nejmoa1409405
105.
Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis · 2022
No notice
106.
Ley TJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 2013;368:2059-2074.
Not in our library10.1056/nejmoa1301689
107.
St Pierre R, Kadoch C. Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities. Curr. Opin. Genet. Dev. 2017;42:56-67.
Not in our library10.1016/j.gde.2017.02.004
108.
Menendez S, Camus S, Izpisua Belmonte JC. p53: guardian of reprogramming. Cell Cycle. 2010;9:3887-3891,.
Not in our library10.4161/cc.9.19.13301
109.
Tschaharganeh DF, et al. p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell. 2014;158:579-592.
Not in our library10.1016/j.cell.2014.05.051
110.
Tosoni D, et al. The Numb/p53 circuitry couples replicative self-renewal and tumor suppression in mammary epithelial cells. J. Cell Biol. 2015;211:845-862.
Not in our library10.1083/jcb.201505037
111.
Kaiser AM, et al. p53 governs an AT1 differentiation programme in lung cancer suppression. Nature. 2023;619:851-859.
Not in our library10.1038/s41586-023-06253-8
112.
Kadur Lakshminarasimha Murthy P, et al. Epigenetic basis of oncogenic-Kras-mediated epithelial-cellular proliferation and plasticity. Dev. Cell. 2022;57:310-328.e319.
Not in our library10.1016/j.devcel.2022.01.006
113.
Fennell L, et al. Braf mutation induces rapid neoplastic transformation in the aged and aberrantly methylated intestinal epithelium. Gut. 2022;71:1127-1140.
Not in our library10.1136/gutjnl-2020-322166
114.
Tao Y, et al. Aging-like spontaneous epigenetic silencing facilitates Wnt activation, stemness, and Braf(V600E)-induced tumorigenesis. Cancer Cell. 2019;35:315-328.e316.
Not in our library10.1016/j.ccell.2019.01.005
115.
Degasperi A, et al. Substitution mutational signatures in whole-genome-sequenced cancers in the UK population. Science. 2022;376:science.abl9283.
Not in our library10.1126/science.abl9283
116.
Shen L, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J. Natl. Cancer Inst. 2005;97:1330-1338.
Not in our library10.1093/jnci/dji275
117.
The co-evolution of the genome and epigenome in colorectal cancer · 2022
No notice
118.
The m6A RNA methylation regulates oncogenic signaling pathways driving cell malignant transformation and carcinogenesis · 2021
No notice
119.
Xu W, et al. METTL3 regulates heterochromatin in mouse embryonic stem cells. Nature. 2021;591:317-321.
Not in our library10.1038/s41586-021-03210-1
120.
Huang H, et al. Histone H3 trimethylation at lysine 36 guides m(6)A RNA modification co-transcriptionally. Nature. 2019;567:414-419.
Not in our library10.1038/s41586-019-1016-7
121.
Li Y, et al. N(6)-Methyladenosine co-transcriptionally directs the demethylation of histone H3K9me2. Nat. Genet. 2020;52:870-877.
Not in our library10.1038/s41588-020-0677-3
122.
Liu J, et al. The RNA m(6)A reader YTHDC1 silences retrotransposons and guards ES cell identity. Nature. 2021;591:322-326.
Not in our library10.1038/s41586-021-03313-9
123.
Nuclear m6A reader YTHDC1 regulates the scaffold function of LINE1 RNA in mouse ESCs and early embryos · 2021
Corrected
124.
Li R, et al. Super-enhancer RNA m(6)A promotes local chromatin accessibility and oncogene transcription in pancreatic ductal adenocarcinoma. Nat. Genet. 2023;55:2224-2234.
Not in our library10.1038/s41588-023-01568-8
125.
Deng S, et al. RNA m(6)A regulates transcription via DNA demethylation and chromatin accessibility. Nat. Genet. 2022;54:1427-1437.
Not in our library10.1038/s41588-022-01173-1
126.
Karin M, Clevers H. Reparative inflammation takes charge of tissue regeneration. Nature. 2016;529:307-315.
Not in our library10.1038/nature17039
127.
Guenin-Mace L, Konieczny P, Naik S. Immune-epithelial cross talk in regeneration and repair. Annu. Rev. Immunol. 2023;41:207-228.
Not in our library10.1146/annurev-immunol-101721-062818
128.
Hanahan D. Hallmarks of cancer: New dimensions. Cancer Discov. 2022;12:31-46.
Not in our library10.1158/2159-8290.cd-21-1059
129.
Denk D, Greten FR. Inflammation: The incubator of the tumor microenvironment. Trends Cancer. 2022;8:901-914.
Not in our library10.1016/j.trecan.2022.07.002
130.
Furman D, et al. Chronic inflammation in the etiology of disease across the life span. Nat. Med. 2019;25:1822-1832.
Not in our library10.1038/s41591-019-0675-0
131.
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-899.
Not in our library10.1016/j.cell.2010.01.025
132.
Inflammation and tumor progression: signaling pathways and targeted intervention · 2021
No notice
133.
Vermeulen L, et al. Defining stem cell dynamics in models of intestinal tumor initiation. Science. 2013;342:995-998.
Not in our library10.1126/science.1243148
134.
Davidson LA, et al. Targeted Deletion of p53 in Lgr5-Expressing Intestinal Stem Cells Promotes Colon Tumorigenesis in a Preclinical Model of Colitis-Associated Cancer. Cancer Res. 2015;75:5392-5397.
Not in our library10.1158/0008-5472.can-15-1706
135.
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution · 2023
No notice
136.
Zhu M, et al. Somatic mutations increase hepatic clonal fitness and regeneration in chronic liver disease. Cell. 2019;177:608-621.e612.
Not in our library10.1016/j.cell.2019.03.026
137.
Kakiuchi N, et al. Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis. Nature. 2020;577:260-265.
Not in our library10.1038/s41586-019-1856-1
138.
Liu K, et al. Sox2 cooperates with inflammation-mediated Stat3 activation in the malignant transformation of foregut basal progenitor cells. Cell. Stem Cell. 2013;12:304-315.
Not in our library10.1016/j.stem.2013.01.007
139.
Todoric J, Karin M. The fire within: Cell-autonomous mechanisms in inflammation-driven cancer. Cancer Cell. 2019;35:714-720.
Not in our library10.1016/j.ccell.2019.04.001
140.
Hill MA, et al. Kras and Tp53 mutations cause cholangiocyte- and hepatocyte-derived cholangiocarcinoma. Cancer Res. 2018;78:4445-4451.
Not in our library10.1158/0008-5472.can-17-1123
141.
Seehawer M, et al. Necroptosis microenvironment directs lineage commitment in liver cancer. Nature. 2018;562:69-75.
Not in our library10.1038/s41586-018-0519-y
142.
Muto T, et al. Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs. Nat. Immunol. 2020;21:535-545.
Not in our library10.1038/s41590-020-0663-z
143.
Hormaechea-Agulla D, et al. Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling. Cell. Stem Cell. 2021;28:1428-1442.e1426.
Not in our library10.1016/j.stem.2021.03.002
144.
Jiang Z, et al. Tff2 defines transit-amplifying pancreatic acinar progenitors that lack regenerative potential and are protective against Kras-driven carcinogenesis. Cell. Stem Cell. 2023;30:1091-1109.e1097.
Not in our library10.1016/j.stem.2023.07.002
145.
Strobel O, et al. In vivo lineage tracing defines the role of acinar-to-ductal transdifferentiation in inflammatory ductal metaplasia. Gastroenterology. 2007;133:1999-2009.
Not in our library10.1053/j.gastro.2007.09.009
146.
Guerra C, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell. 2007;11:291-302.
Not in our library10.1016/j.ccr.2007.01.012
147.
Epigenetic plasticity cooperates with cell-cell interactions to direct pancreatic tumorigenesis · 2023
No notice
148.
Alonso-Curbelo D, et al. A gene–environment-induced epigenetic program initiates tumorigenesis. Nature. 2021;590:642-648.
Not in our library10.1038/s41586-020-03147-x
149.
Li Y, et al. Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer. Nat. Cancer. 2021;2:49-65.
Not in our library10.1038/s43018-020-00134-z
150.
Ge Y, et al. Stem cell lineage infidelity drives wound repair and cancer. Cell. 2017;169:636-650.e614.
Not in our library10.1016/j.cell.2017.03.042
151.
Naik S, et al. Inflammatory memory sensitizes skin epithelial stem cells to tissue damage. Nature. 2017;550:475-480.
Not in our library10.1038/nature24271
152.
Larsen SB, et al. Establishment, maintenance, and recall of inflammatory memory. Cell Stem Cell. 2021;28:1758-1774.e1758.
Not in our library10.1016/j.stem.2021.07.001
153.
Gonzales KAU, et al. Stem cells expand potency and alter tissue fitness by accumulating diverse epigenetic memories. Science. 2021;374:eabh2444.
Not in our library10.1126/science.abh2444
154.
Ordovas-Montanes J, et al. Allergic inflammatory memory in human respiratory epithelial progenitor cells. Nature. 2018;560:649-654.
Not in our library10.1038/s41586-018-0449-8
155.
Lim AI, et al. Prenatal maternal infection promotes tissue-specific immunity and inflammation in offspring. Science. 2021;373:eabf3002.
Not in our library10.1126/science.abf3002
156.
Levra Levron C, Donati G. Multiplicity of stem cell memories of inflammation and tissue repair in epithelia. Trends Cell Biol. 2024;34:3-6.
Not in our library10.1016/j.tcb.2023.10.008
157.
Del Poggetto E, et al. Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science. 2021;373:eabj0486.
Not in our library10.1126/science.abj0486
158.
Naik S, Fuchs E. Inflammatory memory and tissue adaptation in sickness and in health. Nature. 2022;607:249-255.
Not in our library10.1038/s41586-022-04919-3
159.
Levra Levron C, et al. Tissue memory relies on stem cell priming in distal undamaged areas. Nat. Cell Biol. 2023;25:740-753.
Not in our library10.1038/s41556-023-01120-0
160.
Fishbein A, Hammock BD, Serhan CN, Panigrahy D. Carcinogenesis: Failure of resolution of inflammation? Pharmacol. Ther. 2021;218:107670.
Not in our library10.1016/j.pharmthera.2020.107670
161.
Key Characteristics of Carcinogens as a Basis for Organizing Data on Mechanisms of Carcinogenesis · 2015
No notice
162.
Yoshida K, et al. Tobacco smoking and somatic mutations in human bronchial epithelium. Nature. 2020;578:266-272.
Not in our library10.1038/s41586-020-1961-1
163.
Hernando B, et al. The effect of age on the acquisition and selection of cancer driver mutations in sun-exposed normal skin. Ann. Oncol. 2021;32:412-421.
Not in our library10.1016/j.annonc.2020.11.023
164.
Kessler MD, et al. Common and rare variant associations with clonal haematopoiesis phenotypes. Nature. 2022;612:301-309.
Not in our library10.1038/s41586-022-05448-9
165.
Griffin GK, et al. Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin. Nature. 2023;618:834-841.
Not in our library10.1038/s41586-023-06156-8
166.
Fernandez-Antoran D, et al. Outcompeting p53-mutant cells in the normal esophagus by redox manipulation. Cell. Stem Cell. 2019;25:329-341.e326.
Not in our library10.1016/j.stem.2019.06.011
167.
Chen S, et al. Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway. Nat. Commun. 2019;10:5649.
Not in our library10.1038/s41467-019-13542-2
168.
Hermann PC, et al. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. Gastroenterology. 2014;147:1119-1133.e1114.
Not in our library10.1053/j.gastro.2014.08.002
169.
Vaz M, et al. Chronic cigarette smoke-induced epigenomic changes precede sensitization of bronchial epithelial cells to single-step transformation by KRAS mutations. Cancer Cell. 2017;32:360-376.e366.
Not in our library10.1016/j.ccell.2017.08.006
170.
Lung adenocarcinoma promotion by air pollutants · 2023
No notice
171.
Martínez-Reyes I, Chandel NS. Cancer metabolism: Looking forward. Nat. Rev. Cancer. 2021;21:669-680.
Not in our library10.1038/s41568-021-00378-6
172.
Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: Still emerging. Cell Metab. 2022;34:355-377.
Not in our library10.1016/j.cmet.2022.01.007
173.
Evolutionary metabolic landscape from preneoplasia to invasive lung adenocarcinoma · 2021
No notice
174.
Mascaux C, et al. Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature. 2019;571:570-575.
Not in our library10.1038/s41586-019-1330-0
175.
Brunner JS, Finley LWS. Metabolic determinants of tumour initiation. Nat. Rev. Endocrinol. 2023;19:134-150.
Not in our library10.1038/s41574-022-00773-5
176.
Seth Nanda C, Venkateswaran SV, Patani N, Yuneva M. Defining a metabolic landscape of tumours: genome meets metabolism. Br. J. Cancer. 2020;122:136-149.
Not in our library10.1038/s41416-019-0663-7
177.
Morris JP, et al. α-Ketoglutarate links p53 to cell fate during tumour suppression. Nature. 2019;573:595-599.
Not in our library10.1038/s41586-019-1577-5
178.
Carrer A, et al. Acetyl-CoA metabolism supports multistep pancreatic tumorigenesis. Cancer Discov. 2019;9:416-435.
Not in our library10.1158/2159-8290.cd-18-0567
179.
Li JT, et al. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma. Nat. Cell Biol. 2020;22:167-174.
Not in our library10.1038/s41556-019-0455-6
180.
Gunn K, et al. (R)-2-hydroxyglutarate inhibits kdm5 histone lysine demethylases to drive transformation in IDH-mutant cancers. Cancer Discov. 2023;13:1478-1497.
Not in our library10.1158/2159-8290.cd-22-0825
181.
Gallagher EJ, LeRoith D. Hyperinsulinaemia in cancer. Nat. Rev. Cancer. 2020;20:629-644.
Not in our library10.1038/s41568-020-0295-5
182.
López-Suárez A. Burden of cancer attributable to obesity, type 2 diabetes and associated risk factors. Metabolism. 2019;92:136-146.
Not in our library10.1016/j.metabol.2018.10.013
183.
Hirabayashi S, Baranski TJ, Cagan RL. Transformed Drosophila cells evade diet-mediated insulin resistance through wingless signaling. Cell. 2013;154:664-675.
Not in our library10.1016/j.cell.2013.06.030
184.
Sanaki Y, et al. Hyperinsulinemia drives epithelial tumorigenesis by abrogating cell competition. Dev. Cell. 2020;53:379-389.e375.
Not in our library10.1016/j.devcel.2020.04.008
185.
Goncalves MD, et al. High-fructose corn syrup enhances intestinal tumor growth in mice. Science. 2019;363:1345-1349.
Not in our library10.1126/science.aat8515
186.
Chen T, et al. NSUN2 is a glucose sensor suppressing cGAS/STING to maintain tumorigenesis and immunotherapy resistance. Cell Metab. 2023;35:1782-1798.e1788.
Not in our library10.1016/j.cmet.2023.07.009
187.
Sasaki A, et al. Obesity suppresses cell-competition-mediated apical elimination of RasV12-transformed cells from epithelial tissues. Cell Rep. 2018;23:974-982.
Not in our library10.1016/j.celrep.2018.03.104
188.
Kon S, et al. Cell competition with normal epithelial cells promotes apical extrusion of transformed cells through metabolic changes. Nat. Cell Biol. 2017;19:530-541.
Not in our library10.1038/ncb3509
189.
Luo Y, et al. Oncogenic KRAS reduces expression of FGF21 in acinar cells to promote pancreatic tumorigenesis in mice on a high-fat diet. Gastroenterology. 2019;157:1413-1428.e1411.
Not in our library10.1053/j.gastro.2019.07.030
190.
Liu Y, et al. Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ. Nat. Commun. 2022;13:2665.
Not in our library10.1038/s41467-022-30392-7
191.
Yang J, et al. High-fat diet promotes colorectal tumorigenesis through modulating gut microbiota and metabolites. Gastroenterology. 2022;162:135-149.e132.
Not in our library10.1053/j.gastro.2021.08.041
192.
The Integrative Human Microbiome Project · 2019
No notice
193.
Yang J, et al. Comprehensive analyses reveal effects on tumor immune infiltration and immunotherapy response of APOBEC mutagenesis and its molecular mechanisms in esophageal squamous cell carcinoma. Int. J. Biol. Sci. 2023;19:2551-2571.
Not in our library10.7150/ijbs.83824
194.
Knippel RJ, Drewes JL, Sears CL. The cancer microbiome: Recent highlights and knowledge gaps. Cancer Discov. 2021;11:2378-2395.
Not in our library10.1158/2159-8290.cd-21-0324
195.
Dohlman AB, et al. The cancer microbiome atlas: a pan-cancer comparative analysis to distinguish tissue-resident microbiota from contaminants. Cell Host Microbe. 2021;29:281-298.e285.
Not in our library10.1016/j.chom.2020.12.001
196.
Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions · 2022
No notice
197.
Poore GD, et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature. 2020;579:567-574.
Not in our library10.1038/s41586-020-2095-1
198.
Wang N, Fang J-Y. Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer. Trends Microbiol. 2023;31:159-172.
Not in our library10.1016/j.tim.2022.08.010
199.
Dejea CM, et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science. 2018;359:592-597.
Not in our library10.1126/science.aah3648
200.
Toprak NU, et al. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin. Microbiol. Infect. 2006;12:782-786.
Not in our library10.1111/j.1469-0691.2006.01494.x
201.
Yachida S, et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat. Med. 2019;25:968-976.
Not in our library10.1038/s41591-019-0458-7
202.
Chen F, et al. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma. Gut. 2022;71:1315-1325.
Not in our library10.1136/gutjnl-2020-323476
203.
Altered gut metabolites and microbiota interactions are implicated in colorectal carcinogenesis and can be non-invasive diagnostic biomarkers · 2022
No notice
204.
Coker OO, et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut. 2018;67:1024-1032.
Not in our library10.1136/gutjnl-2017-314281
205.
Interaction between the microbiome and TP53 in human lung cancer · 2018
Corrected
206.
Parida S, et al. A procarcinogenic colon microbe promotes breast tumorigenesis and metastatic progression and concomitantly activates notch and β-catenin axes. Cancer Discov. 2021;11:1138-1157.
Not in our library10.1158/2159-8290.cd-20-0537
207.
Sepich-Poore GD, et al. The microbiome and human cancer. Science. 2021;371:eabc4552.
Not in our library10.1126/science.abc4552
208.
Cullin N, et al. Microbiome and cancer. Cancer Cell. 2021;39:1317-1341.
Not in our library10.1016/j.ccell.2021.08.006
209.
Yeh SH, et al. Hepatitis B virus DNA integration drives carcinogenesis and provides a new biomarker for HBV-related HCC. Cell. Mol. Gastroenterol. Hepatol. 2023;15:921-929.
Not in our library10.1016/j.jcmgh.2023.01.001
210.
Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J. Hepatol. 2010;52:594-604.
Not in our library10.1016/j.jhep.2009.10.033
211.
Li CL, et al. Androgen receptor enhances hepatic telomerase reverse transcriptase gene transcription after hepatitis B virus integration or point mutation in promoter region. Hepatology. 2019;69:498-512.
Not in our library10.1002/hep.30201
212.
Péneau C, et al. Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. Gut. 2022;71:616-626.
Not in our library10.1136/gutjnl-2020-323153
213.
Nault JC, Ningarhari M, Rebouissou S, Zucman-Rossi J. The role of telomeres and telomerase in cirrhosis and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 2019;16:544-558.
Not in our library10.1038/s41575-019-0165-3
214.
Wang J, Chenivesse X, Henglein B, Bréchot C. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature. 1990;343:555-557.
Not in our library10.1038/343555a0
215.
Wang J, et al. Modification of cyclin A expression by hepatitis B virus DNA integration in a hepatocellular carcinoma. Oncogene. 1992;7:1653-1656.
Not in our library
216.
Berasain C, et al. Oncogenic activation of a human cyclin A2 targeted to the endoplasmic reticulum upon hepatitis B virus genome insertion. Oncogene. 1998;16:1277-1288.
Not in our library10.1038/sj.onc.1201893
217.
Pleguezuelos-Manzano C, et al. Mutational signature in colorectal cancer caused by genotoxic pks(+) E. coli. Nature. 2020;580:269-273.
Not in our library10.1038/s41586-020-2080-8
218.
The Colibactin Genotoxin Generates DNA Interstrand Cross-Links in Infected Cells · 2018
No notice
219.
DeStefano Shields CE, et al. Bacterial-driven inflammation and mutant BRAF expression combine to promote murine colon tumorigenesis that is sensitive to immune checkpoint therapy. Cancer Discov. 2021;11:1792-1807.
Not in our library10.1158/2159-8290.cd-20-0770
220.
Kadosh E, et al. The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. Nature. 2020;586:133-138.
Not in our library10.1038/s41586-020-2541-0
221.
Fu K, et al. Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice. Cell. 2024;187:882-896.e817.
Not in our library10.1016/j.cell.2024.01.004
222.
Pushalkar S, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 2018;8:403-416.
Not in our library10.1158/2159-8290.cd-17-1134
223.
Aykut B, et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature. 2019;574:264-267.
Not in our library10.1038/s41586-019-1608-2
224.
Zhang X, et al. Tissue-resident Lachnospiraceae family bacteria protect against colorectal carcinogenesis by promoting tumor immune surveillance. Cell Host Microbe. 2023;31:418-432.e418.
Not in our library10.1016/j.chom.2023.01.013
225.
Chen H, et al. Urea cycle activation triggered by host-microbiota maladaptation driving colorectal tumorigenesis. Cell Metab. 2023;35:651-666.e657.
Not in our library10.1016/j.cmet.2023.03.003
226.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA. Cancer J. Clin. 2018;68:7-30.
Not in our library10.3322/caac.21442
227.
López-Otín C, et al. Meta-hallmarks of aging and cancer. Cell Metab. 2023;35:12-35.
Not in our library10.1016/j.cmet.2022.11.001
228.
Schmitt CA, Wang B, Demaria M. Senescence and cancer - role and therapeutic opportunities. Nat. Rev. Clin. Oncol. 2022;19:619-636.
Not in our library10.1038/s41571-022-00668-4
229.
Stern JL, et al. Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. Genes Dev. 2015;29:2219-2224.
Not in our library10.1101/gad.269498.115
230.
Cellular senescence and chronological age in various human tissues: A systematic review and meta‐analysis · 2019
No notice
231.
The landscape of human tissue and cell type specific expression and co-regulation of senescence genes · 2022
No notice
232.
Faget DV, Ren Q, Stewart SA. Unmasking senescence: context-dependent effects of SASP in cancer. Nat. Rev. Cancer. 2019;19:439-453.
Not in our library10.1038/s41568-019-0156-2
233.
Igarashi N, et al. Hepatocyte growth factor derived from senescent cells attenuates cell competition-induced apical elimination of oncogenic cells. Nat. Commun. 2022;13:4157.
Not in our library10.1038/s41467-022-31642-4
234.
Prieto LI, et al. Senescent alveolar macrophages promote early-stage lung tumorigenesis. Cancer Cell. 2023;41:1261-1275.e1266.
Not in our library10.1016/j.ccell.2023.05.006
235.
Haston S, et al. Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer. Cancer Cell. 2023;41:1242-1260.e1246.
Not in our library10.1016/j.ccell.2023.05.004
236.
Visvader JE. Cells of origin in cancer. Nature. 2011;469:314-322.
Not in our library10.1038/nature09781
237.
Hayakawa Y, et al. Stem cells and origins of cancer in the upper gastrointestinal tract. Cell. Stem Cell. 2021;28:1343-1361.
Not in our library10.1016/j.stem.2021.05.012
238.
Sánchez-Danés A, Blanpain C. Deciphering the cells of origin of squamous cell carcinomas. Nat. Rev. Cancer. 2018;18:549-561.
Not in our library10.1038/s41568-018-0024-5
239.
Barker N, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature. 2008;457:608-611.
Not in our library10.1038/nature07602
240.
Baggiolini A, et al. Developmental chromatin programs determine oncogenic competence in melanoma. Science. 2021;373:eabc1048.
Not in our library10.1126/science.abc1048
241.
Boussouar F, et al. Malignant genome reprogramming by ATAD2. Biochim. Biophys. Acta. 2013;1829:1010-1014.
Not in our library10.1016/j.bbagrm.2013.06.003
242.
Chaffer CL, et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell. 2013;154:61-74.
Not in our library10.1016/j.cell.2013.06.005
243.
Schwitalla S, et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell. 2013;152:25-38.
Not in our library10.1016/j.cell.2012.12.012
244.
Friedmann-Morvinski D, et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science. 2012;338:1080-1084.
Not in our library10.1126/science.1226929
245.
Köhler C, et al. Mouse cutaneous melanoma induced by mutant braf arises from expansion and dedifferentiation of mature pigmented melanocytes. Cell. Stem Cell. 2017;21:679-693.e676.
Not in our library10.1016/j.stem.2017.08.003
246.
Kaufman CK, et al. A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation. Science. 2016;351:aad2197.
Not in our library10.1126/science.aad2197
247.
Van Keymeulen A, et al. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature. 2015;525:119-123.
Not in our library10.1038/nature14665
248.
Molyneux G, et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell. Stem Cell. 2010;7:403-417.
Not in our library10.1016/j.stem.2010.07.010
249.
Lim E, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 2009;15:907-913.
Not in our library10.1038/nm.2000
250.
MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state · 2018
Corrected
251.
Concepcion CP, et al. Smarca4 inactivation promotes lineage-specific transformation and early metastatic features in the lung. Cancer Discov. 2022;12:562-585.
Not in our library10.1158/2159-8290.cd-21-0248
252.
Chen Y, et al. Club cells employ regeneration mechanisms during lung tumorigenesis. Nat. Commun. 2022;13:4557.
Not in our library10.1038/s41467-022-32052-2
253.
An atlas of epithelial cell states and plasticity in lung adenocarcinoma · 2024
Corrected
254.
Marjanovic ND, et al. Emergence of a high-plasticity cell state during lung cancer evolution. Cancer Cell. 2020;38:229-246.e213.
Not in our library10.1016/j.ccell.2020.06.012
255.
Kopp JL, et al. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;22:737-750.
Not in our library10.1016/j.ccr.2012.10.025
256.
Wei D, et al. KLF4 is essential for induction of cellular identity change and acinar-to-ductal reprogramming during early pancreatic carcinogenesis. Cancer Cell. 2016;29:324-338.
Not in our library10.1016/j.ccell.2016.02.005
257.
Pastushenko I, et al. Identification of the tumour transition states occurring during EMT. Nature. 2018;556:463-468.
Not in our library10.1038/s41586-018-0040-3
258.
Puram SV, et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell. 2017;171:1611-1624.e1624.
Not in our library10.1016/j.cell.2017.10.044
259.
Chen L, et al. Aberrant epithelial cell interaction promotes esophageal squamous-cell carcinoma development and progression. Signal Transduct. Target. Ther. 2023;8:453.
Not in our library10.1038/s41392-023-01710-2
260.
Pastushenko I, et al. Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. Nature. 2021;589:448-455.
Not in our library10.1038/s41586-020-03046-1
261.
Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer · 2022
No notice
262.
Chen B, et al. Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. Cell. 2021;184:6262-6280.e6226.
Not in our library10.1016/j.cell.2021.11.031
263.
Sethi NS, et al. Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. Nat. Genet. 2020;52:219-230.
Not in our library10.1038/s41588-019-0574-9
264.
Qin X, et al. An oncogenic phenoscape of colonic stem cell polarization. Cell. 2023;186:5554-5568.e5518.
Not in our library10.1016/j.cell.2023.11.004
265.
Tanimura N, Fujita Y. Epithelial defense against cancer (EDAC). Semin. Cancer Biol. 2020;63:44-48.
Not in our library10.1016/j.semcancer.2019.05.011
266.
Baker NE. Emerging mechanisms of cell competition. Nat. Rev. Genet. 2020;21:683-697.
Not in our library10.1038/s41576-020-0262-8
267.
van Neerven SM, Vermeulen L. Cell competition in development, homeostasis and cancer. Nat. Rev. Mol. Cell. Biol. 2023;24:221-236.
Not in our library10.1038/s41580-022-00538-y
268.
Hill W, et al. EPHA2-dependent outcompetition of KRASG12D mutant cells by wild-type neighbors in the adult pancreas. Curr. Biol. 2021;31:2550-2560.e2555.
Not in our library10.1016/j.cub.2021.03.094
269.
Ritsma L, et al. Intestinal crypt homeostasis revealed at single-stem-cell level by in vivo live imaging. Nature. 2014;507:362-365.
Not in our library10.1038/nature12972
270.
Flanagan DJ, et al. NOTUM from Apc-mutant cells biases clonal competition to initiate cancer. Nature. 2021;594:430-435.
Not in our library10.1038/s41586-021-03525-z
271.
van Neerven SM, et al. Apc-mutant cells act as supercompetitors in intestinal tumour initiation. Nature. 2021;594:436-441.
Not in our library10.1038/s41586-021-03558-4
272.
Yum MK, et al. Tracing oncogene-driven remodelling of the intestinal stem cell niche. Nature. 2021;594:442-447.
Not in our library10.1038/s41586-021-03605-0
273.
Avagyan S, et al. Resistance to inflammation underlies enhanced fitness in clonal hematopoiesis. Science. 2021;374:768-772.
Not in our library10.1126/science.aba9304
274.
Bejarano L, Jordāo MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11:933-959.
Not in our library10.1158/2159-8290.cd-20-1808
275.
Philip M, Schietinger A. CD8(+) T cell differentiation and dysfunction in cancer. Nat. Rev. Immunol. 2022;22:209-223.
Not in our library10.1038/s41577-021-00574-3
276.
Lavin Y, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell. 2017;169:750-765.e717.
Not in our library10.1016/j.cell.2017.04.014
277.
van der Leun AM, Thommen DS, Schumacher TN. CD8(+) T cell states in human cancer: Insights from single-cell analysis. Nat. Rev. Cancer. 2020;20:218-232.
Not in our library10.1038/s41568-019-0235-4
278.
de Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374-403.
Not in our library10.1016/j.ccell.2023.02.016
279.
Roelands J, et al. Transcriptomic and immunophenotypic profiling reveals molecular and immunological hallmarks of colorectal cancer tumourigenesis. Gut. 2023;72:1326-1339.
Not in our library10.1136/gutjnl-2022-327608
280.
Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features · 2021
No notice
281.
Pennycuick A, et al. Immune surveillance in clinical regression of preinvasive squamous cell lung cancer. Cancer Discov. 2020;10:1489-1499.
Not in our library10.1158/2159-8290.cd-19-1366
282.
van Weverwijk A, de Visser KE. Mechanisms driving the immunoregulatory function of cancer cells. Nat. Rev. Cancer. 2023;23:193-215.
Not in our library10.1038/s41568-022-00544-4
283.
Caronni N, et al. IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer. Nature. 2023;623:415-422.
Not in our library10.1038/s41586-023-06685-2
284.
Yuan S, et al. Ras drives malignancy through stem cell crosstalk with the microenvironment. Nature. 2022;612:555-563.
Not in our library10.1038/s41586-022-05475-6
285.
Immune modulatory effects of oncogenic KRAS in cancer · 2020
No notice
286.
Sugiyama E, et al. Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non–small cell lung cancer. Sci. Immunol. 2020;5:eaav3937.
Not in our library10.1126/sciimmunol.aav3937
287.
Cooks T, et al. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell. 2013;23:634-646.
Not in our library10.1016/j.ccr.2013.03.022
288.
Ghosh M, et al. Mutant p53 suppresses innate immune signaling to promote tumorigenesis. Cancer Cell. 2021;39:494-508.e495.
Not in our library10.1016/j.ccell.2021.01.003
289.
Kohanbash G, et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J. Clin. Invest. 2017;127:1425-1437.
Not in our library10.1172/jci90644
290.
Dias Carvalho P, et al. KRAS oncogenic signaling extends beyond cancer cells to orchestrate the microenvironment. Cancer Res. 2018;78:7-14.
Not in our library10.1158/0008-5472.can-17-2084
291.
Lawson KA, et al. Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. Nature. 2020;586:120-126.
Not in our library10.1038/s41586-020-2746-2
292.
Martin TD, et al. The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation. Science. 2021;373:1327-1335.
Not in our library10.1126/science.abg5784
293.
Goto N, et al. SOX17 enables immune evasion of early colorectal adenomas and cancers. Nature. 2024;627:636-645.
Not in our library10.1038/s41586-024-07135-3
294.
Wu Z, et al. Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence. Nat. Genet. 2021;53:881-894.
Not in our library10.1038/s41588-021-00859-2
295.
Watson MJ, et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 2021;591:645-651.
Not in our library10.1038/s41586-020-03045-2
296.
Colegio OR, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513:559-563.
Not in our library10.1038/nature13490
297.
Kloosterman DJ, Akkari L. Macrophages at the interface of the co-evolving cancer ecosystem. Cell. 2023;186:1627-1651.
Not in our library10.1016/j.cell.2023.02.020
298.
Reinfeld BI, et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature. 2021;593:282-288.
Not in our library10.1038/s41586-021-03442-1
299.
Zhang X, et al. Reprogramming tumour-associated macrophages to outcompete cancer cells. Nature. 2023;619:616-623.
Not in our library10.1038/s41586-023-06256-5
300.
Yarchoan M, et al. Targeting neoantigens to augment antitumour immunity. Nat. Rev. Cancer. 2017;17:209-222.
Not in our library10.1038/nrc.2016.154
301.
Hoyos D, et al. Fundamental immune-oncogenicity trade-offs define driver mutation fitness. Nature. 2022;606:172-179.
Not in our library10.1038/s41586-022-04696-z
302.
Heiser CN, et al. Molecular cartography uncovers evolutionary and microenvironmental dynamics in sporadic colorectal tumors. Cell. 2023;186:5620-5637.e5616.
Not in our library10.1016/j.cell.2023.11.006
303.
Roulis M, et al. Paracrine orchestration of intestinal tumorigenesis by a mesenchymal niche. Nature. 2020;580:524-529.
Not in our library10.1038/s41586-020-2166-3
304.
A framework for advancing our understanding of cancer-associated fibroblasts · 2020
No notice
305.
Chhabra Y, Weeraratna AT. Fibroblasts in cancer: Unity in heterogeneity. Cell. 2023;186:1580-1609.
Not in our library10.1016/j.cell.2023.03.016
306.
Caligiuri G, Tuveson DA. Activated fibroblasts in cancer: Perspectives and challenges. Cancer Cell. 2023;41:434-449.
Not in our library10.1016/j.ccell.2023.02.015
307.
Chen Y, et al. Epithelial cells activate fibroblasts to promote esophageal cancer development. Cancer Cell. 2023;41:903-918.e908.
Not in our library10.1016/j.ccell.2023.03.001
308.
Strell C, et al. Impact of epithelial-stromal interactions on peritumoral fibroblasts in ductal carcinoma in situ. J. Natl Cancer Inst. 2019;111:983-995.
Not in our library10.1093/jnci/djy234
309.
Erez N, et al. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell. 2010;17:135-147.
Not in our library10.1016/j.ccr.2009.12.041
310.
Esbona K, et al. COX-2 modulates mammary tumor progression in response to collagen density. Breast Cancer Res. 2016;18:35.
Not in our library10.1186/s13058-016-0695-3
311.
Guo Q, et al. Physiologically activated mammary fibroblasts promote postpartum mammary cancer. JCI Insight. 2017;2:e89206.
Not in our library10.1172/jci.insight.89206
312.
Tsai KK, Chuang EY, Little JB, Yuan ZM. Cellular mechanisms for low-dose ionizing radiation-induced perturbation of the breast tissue microenvironment. Cancer Res. 2005;65:6734-6744,.
Not in our library10.1158/0008-5472.can-05-0703
313.
Hu B, et al. Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell. 2012;149:1207-1220.
Not in our library10.1016/j.cell.2012.03.048
314.
Extracellular matrix and its therapeutic potential for cancer treatment · 2021
No notice
315.
Mouw JK, Ou G, Weaver VM. Extracellular matrix assembly: a multiscale deconstruction. Nat. Rev. Mol. Cell. Biol. 2014;15:771-785,.
Not in our library10.1038/nrm3902
316.
Mohammadi H, Sahai E. Mechanisms and impact of altered tumour mechanics. Nat. Cell Biol. 2018;20:766-774.
Not in our library10.1038/s41556-018-0131-2
317.
Wu, C., Weis, S. M. & Cheresh, D. A. Tumor-initiating cells establish a niche to overcome isolation stress. Trends Cell Biol. 10.1016/j.tcb.2023.08.001 (2023).
Not in our library10.1016/j.tcb.2023.08.001
318.
Wu C, et al. Pancreatic cancer cells upregulate LPAR4 in response to isolation stress to promote an ECM-enriched niche and support tumour initiation. Nat. Cell Biol. 2023;25:309-322.
Not in our library10.1038/s41556-022-01055-y
319.
Lampi MC, Reinhart-King CA. Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials. Sci. Transl. Med. 2018;10:eaao0475.
Not in our library10.1126/scitranslmed.aao0475
320.
Pothapragada SP, Gupta P, Mukherjee S, Das T. Matrix mechanics regulates epithelial defence against cancer by tuning dynamic localization of filamin. Nat. Commun. 2022;13:218.
Not in our library10.1038/s41467-021-27896-z
321.
Bansaccal N, et al. The extracellular matrix dictates regional competence for tumour initiation. Nature. 2023;623:828-835.
Not in our library10.1038/s41586-023-06740-y
322.
Panciera T, et al. Reprogramming normal cells into tumour precursors requires ECM stiffness and oncogene-mediated changes of cell mechanical properties. Nat. Mater. 2020;19:797-806.
Not in our library10.1038/s41563-020-0615-x
323.
Matrix viscoelasticity promotes liver cancer progression in the pre-cirrhotic liver · 2024
Corrected
324.
Panciera T, Azzolin L, Cordenonsi M, Piccolo S. Mechanobiology of YAP and TAZ in physiology and disease. Nat. Rev. Mol. Cell. Biol. 2017;18:758-770.
Not in our library10.1038/nrm.2017.87
325.
Levayer R. Solid stress, competition for space and cancer: The opposing roles of mechanical cell competition in tumour initiation and growth. Semin. Cancer Biol. 2020;63:69-80.
Not in our library10.1016/j.semcancer.2019.05.004
326.
Schlegelmilch K, et al. Yap1 acts downstream of α-catenin to control epidermal proliferation. Cell. 2011;144:782-795.
Not in our library10.1016/j.cell.2011.02.031
327.
Kostiou V, Hall MWJ, Jones PH, Hall BA. Simulations reveal that different responses to cell crowding determine the expansion of p53 and Notch mutant clones in squamous epithelia. J. R. Soc. Interface. 2021;18:20210607.
Not in our library10.1098/rsif.2021.0607
328.
Mechanical cell competition kills cells via induction of lethal p53 levels · 2016
No notice
329.
Moreno E, Valon L, Levillayer F, Levayer R. Competition for space induces cell elimination through compaction-driven ERK downregulation. Curr. Biol. 2019;29:23-34.e28.
Not in our library10.1016/j.cub.2018.11.007
330.
Leung CT, Brugge JS. Outgrowth of single oncogene-expressing cells from suppressive epithelial environments. Nature. 2012;482:410-413,.
Not in our library10.1038/nature10826
331.
Liu N, et al. Stem cell competition orchestrates skin homeostasis and ageing. Nature. 2019;568:344-350.
Not in our library10.1038/s41586-019-1085-7
332.
Brunner SF, et al. Somatic mutations and clonal dynamics in healthy and cirrhotic human liver. Nature. 2019;574:538-542.
Not in our library10.1038/s41586-019-1670-9
333.
Boone PG, et al. A cancer rainbow mouse for visualizing the functional genomics of oncogenic clonal expansion. Nat. Commun. 2019;10:5490.
Not in our library10.1038/s41467-019-13330-y
334.
Lee-Six H, et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature. 2019;574:532-537.
Not in our library10.1038/s41586-019-1672-7
335.
Baker A-M, et al. Crypt fusion as a homeostatic mechanism in the human colon. Gut. 2019;68:1986-1993.
Not in our library10.1136/gutjnl-2018-317540
336.
Olpe C, et al. A diffusion-like process accommodates new crypts during clonal expansion in human colonic epithelium. Gastroenterology. 2021;161:548-559.e523.
Not in our library10.1053/j.gastro.2021.04.035
337.
Nyga A, et al. Oncogenic RAS instructs morphological transformation of human epithelia via differential tissue mechanics. SCI Adv. 2021;7:eabg6467.
Not in our library10.1126/sciadv.abg6467
338.
Messal HA, et al. Tissue curvature and apicobasal mechanical tension imbalance instruct cancer morphogenesis. Nature. 2019;566:126-130.
Not in our library10.1038/s41586-019-0891-2
339.
Fiore VF, et al. Mechanics of a multilayer epithelium instruct tumour architecture and function. Nature. 2020;585:433-439.
Not in our library10.1038/s41586-020-2695-9
340.
Curtius K, Wright NA, Graham TA. An evolutionary perspective on field cancerization. Nat. Rev. Cancer. 2018;18:19-32.
Not in our library10.1038/nrc.2017.102
341.
Lambert SA, Abraham G, Inouye M. Towards clinical utility of polygenic risk scores. Hum. Mol. Genet. 2019;28:R133-r142.
Not in our library10.1093/hmg/ddz187
342.
Spira A, et al. Precancer atlas to drive precision prevention trials. Cancer Res. 2017;77:1510-1541.
Not in our library10.1158/0008-5472.can-16-2346
343.
Lee A, et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet. Med. 2019;21:1708-1718.
Not in our library10.1038/s41436-018-0406-9
344.
van der Wel MJ, et al. Improved diagnostic stratification of digitised Barrett’s oesophagus biopsies by p53 immunohistochemical staining. Histopathology. 2018;72:1015-1023.
Not in our library10.1111/his.13462
345.
Redston M, et al. Abnormal TP53 predicts risk of progression in patients with Barrett’s esophagus regardless of a diagnosis of dysplasia. Gastroenterology. 2022;162:468-481.
Not in our library10.1053/j.gastro.2021.10.038
346.
Davison JM, et al. Independent blinded validation of a tissue systems pathology test to predict progression in patients with Barrett’s esophagus. Am. J. Gastroenterol. 2020;115:843-852.
Not in our library10.14309/ajg.0000000000000556
347.
Lin S-H, et al. The somatic mutation landscape of premalignant colorectal adenoma. Gut. 2018;67:1299-1305.
Not in our library10.1136/gutjnl-2016-313573
348.
Desai P, et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat. Med. 2018;24:1015-1023.
Not in our library10.1038/s41591-018-0081-z
349.
Weeks, L. D. et al. Prediction of risk for myeloid malignancy in clonal hematopoiesis. NEJM Evid. 2, EVIDoa2200310 (2023).
Not in our library10.1056/evidoa2200310
350.
Gu M, et al. Multiparameter prediction of myeloid neoplasia risk. Nat. Genet. 2023;55:1523-1530.
Not in our library10.1038/s41588-023-01472-1
351.
Killcoyne S, et al. Genomic copy number predicts esophageal cancer years before transformation. Nat. Med. 2020;26:1726-1732.
Not in our library10.1038/s41591-020-1033-y
352.
Douville C, et al. Massively parallel sequencing of esophageal brushings enables an aneuploidy-based classification of patients with Barrett’s esophagus. Gastroenterology. 2021;160:2043-2054.e2042.
Not in our library10.1053/j.gastro.2021.01.209
353.
Timmer MR, et al. Derivation of genetic biomarkers for cancer risk stratification in Barrett’s oesophagus: a prospective cohort study. Gut. 2016;65:1602-1610.
Not in our library10.1136/gutjnl-2015-309642
354.
Hadjinicolaou AV, et al. Aneuploidy in targeted endoscopic biopsies outperforms other tissue biomarkers in the prediction of histologic progression of Barrett’s oesophagus: A multi-centre prospective cohort study. EBioMedicine. 2020;56:102765.
Not in our library10.1016/j.ebiom.2020.102765
355.
Abelson S, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559:400-404.
Not in our library10.1038/s41586-018-0317-6
356.
Salk JJ, et al. Clonal expansions in ulcerative colitis identify patients with neoplasia. Proc. Natl. Acad. Sci. USA. 2009;106:20871-20876.
Not in our library10.1073/pnas.0909428106
357.
Dhawan A, Graham TA, Fletcher AG. A computational modeling approach for deriving biomarkers to predict cancer risk in premalignant disease. Cancer Prev. Res. (Phila. Pa.). 2016;9:283-295.
Not in our library10.1158/1940-6207.capr-15-0248
358.
Martinez P, et al. Dynamic clonal equilibrium and predetermined cancer risk in Barrett’s oesophagus. Nat. Commun. 2016;7:12158.
Not in our library10.1038/ncomms12158
359.
Maley CC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 2006;38:468-473.
Not in our library10.1038/ng1768
360.
Moinova HR, et al. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett’s esophagus. Sci. Transl. Med. 2018;10:eaao5848.
Not in our library10.1126/scitranslmed.aao5848
361.
Iyer PG, et al. Accurate nonendoscopic detection of Barrett’s esophagus by methylated DNA markers: A multisite case control study. Am. J. Gastroenterol. 2020;115:1201-1209.
Not in our library10.14309/ajg.0000000000000656
362.
Jin Z, et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett’s esophagus. Cancer Res. 2009;69:4112-4115.
Not in our library10.1158/0008-5472.can-09-0028
363.
Yu M, et al. Novel DNA methylation biomarker panel for detection of esophageal adenocarcinoma and high-grade dysplasia. Clin. Cancer Res. 2022;28:3761-3769.
Not in our library10.1158/1078-0432.ccr-22-0445
364.
Klein EA, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann. Oncol. 2021;32:1167-1177.
Not in our library10.1016/j.annonc.2021.05.806
365.
Razavi P, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat. Med. 2019;25:1928-1937.
Not in our library10.1038/s41591-019-0652-7
366.
Risom T, et al. Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. Cell. 2022;185:299-310.e218.
Not in our library10.1016/j.cell.2021.12.023
367.
Poutanen M, Hagberg Thulin M, Härkönen P. Targeting sex steroid biosynthesis for breast and prostate cancer therapy. Nat. Rev. Cancer. 2023;23:686-709.
Not in our library10.1038/s41568-023-00609-y
368.
Owens DK, et al. Medication use to reduce risk of breast cancer: US preventive services task force recommendation statement. JAMA. 2019;322:857-867.
Not in our library10.1001/jama.2019.11885
369.
Nelson HD, et al. Medication use for the risk reduction of primary breast cancer in women: Updated evidence report and systematic review for the US preventive services task force. JAMA. 2019;322:868-886.
Not in our library10.1001/jama.2019.5780
370.
Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: Weighing the evidence. Eur. Urol. 2013;63:800-809,.
Not in our library10.1016/j.eururo.2012.11.013
371.
Thompson IM, et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 2003;349:215-224.
Not in our library10.1056/nejmoa030660
372.
Andriole GL, et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 2010;362:1192-1202.
Not in our library10.1056/nejmoa0908127
373.
Wang S, et al. Association of aspirin therapy with risk of hepatocellular carcinoma: A systematic review and dose-response analysis of cohort studies with 2.5 million participants. Pharmacol. Res. 2020;151:104585.
Not in our library10.1016/j.phrs.2019.104585
374.
Hua H, et al. Complex roles of the old drug aspirin in cancer chemoprevention and therapy. Med. Res. Rev. 2019;39:114-145.
Not in our library10.1002/med.21514
375.
Dehmer SP, et al. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force. JAMA. 2022;327:1598-1607.
Not in our library10.1001/jama.2022.3385
376.
National Guideline Alliance (UK). Effectiveness of aspirin in the prevention of colorectal cancer in people with Lynch syndrome. (National Institute for Health and Care Excellence (NICE), 2020).
Not in our library
377.
Ishikawa H, et al. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial. Lancet Gastroenterol. Hepatol. 2021;6:474-481.
Not in our library10.1016/s2468-1253(21)00018-2
378.
Ridker PM, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1833-1842.
Not in our library10.1016/s0140-6736(17)32247-x
379.
Kurelac I, et al. The multifaceted effects of metformin on tumor microenvironment. Semin. Cell Dev. Biol. 2020;98:90-97.
Not in our library10.1016/j.semcdb.2019.05.010
380.
Zhao H, Swanson KD, Zheng B. Therapeutic Repurposing of Biguanides in Cancer. Trends Cancer. 2021;7:714-730.
Not in our library10.1016/j.trecan.2021.03.001
381.
Herms, A. et al. Levelling out differences in aerobic glycolysis neutralizes the competitive advantage of oncogenic PIK3CA mutant progenitors in the esophagus. Preprint at https://www.biorxiv.org/content/10.1101/2021.05.28.446104v1 (2021).
Not in our library
382.
Evans JMM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304-1305.
Not in our library10.1136/bmj.38415.708634.f7
383.
Higurashi T, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol. 2016;17:475-483.
Not in our library10.1016/s1470-2045(15)00565-3
384.
Yu OHY, Suissa S. Metformin and cancer: Solutions to a real-world evidence failure. Diabetes Care. 2023;46:904-912.
Not in our library10.2337/dci22-0047
385.
Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 2012;367:1792-1802,.
Not in our library10.1056/nejmoa1201735
386.
Ren Q-W, et al. Statin associated lower cancer risk and related mortality in patients with heart failure. Eur. Heart J. 2021;42:3049-3059.
Not in our library10.1093/eurheartj/ehab325
387.
Zeng RW, et al. Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. Aliment. Pharmacol. Ther. 2023;57:600-609.
Not in our library10.1111/apt.17371
388.
Wang Y, et al. A meta-analysis of statin use and risk of hepatocellular carcinoma. Can. J. Gastroenterol. Hepatol. 2022;2022:5389044.
Not in our library10.1155/2022/5389044
389.
Allott EH, et al. Statin use is associated with lower risk of PTEN-null and lethal prostate cancer. Clin. Cancer Res. 2020;26:1086-1093.
Not in our library10.1158/1078-0432.ccr-19-2853
390.
Flick ED, et al. Statin use and risk of prostate cancer in the California Men’s Health Study cohort. Cancer Epidemiol. Biomark. Prev. 2007;16:2218-2225.
Not in our library10.1158/1055-9965.epi-07-0197
391.
Previous Exposure to Statin May Reduce the Risk of Subsequent Non-Hodgkin Lymphoma: A Nationwide Population-Based Case-Control Study. · 2015
Not checked
392.
Poynter JN, et al. Statins and the risk of colorectal cancer. N. Engl. J. Med. 2005;352:2184-2192.
Not in our library10.1056/nejmoa043792
393.
Cheung K-S, et al. Statins reduce the progression of non-advanced adenomas to colorectal cancer: a postcolonoscopy study in 187 897 patients. Gut. 2019;68:1979-1985.
Not in our library10.1136/gutjnl-2018-317714
394.
Demierre M-F, et al. Statins and cancer prevention. Nat. Rev. Cancer. 2005;5:930-942.
Not in our library10.1038/nrc1751
395.
Han J-X, et al. Microbiota-derived tryptophan catabolites mediate the chemopreventive effects of statins on colorectal cancer. Nat. Microbiol. 2023;8:919-933.
Not in our library10.1038/s41564-023-01363-5
396.
Joyce R, et al. Identification of aberrant luminal progenitors and mTORC1 as a potential breast cancer prevention target in BRCA2 mutation carriers. Nat. Cell Biol. 2024;26:138-152.
Not in our library10.1038/s41556-023-01315-5
397.
Peuget S, Zhou X, Selivanova G. Translating p53-based therapies for cancer into the clinic. Nat. Rev. Cancer. 2024;24:192-215.
Not in our library10.1038/s41568-023-00658-3
398.
Falcaro M, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398:2084-2092.
Not in our library10.1016/s0140-6736(21)02178-4
399.
Trimble CL, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386:2078-2088.
Not in our library10.1016/s0140-6736(15)00239-1
400.
Chen D-S. Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. J. Hepatol. 2009;50:805-816.
Not in our library10.1016/j.jhep.2009.01.002
401.
Chang M-H, et al. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology. 2016;151:472-480. e471.
Not in our library10.1053/j.gastro.2016.05.048
402.
McMahon BJ, et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology. 2011;54:801-807.
Not in our library10.1002/hep.24442
403.
Chien Y-C, et al. Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: a 20-year cohort study of 3.8 million vaccinees. Hepatology. 2014;60:125-132.
Not in our library10.1002/hep.27048
404.
Finn OJ. The dawn of vaccines for cancer prevention. Nat. Rev. Immunol. 2018;18:183-194.
Not in our library10.1038/nri.2017.140
405.
Czerniecki BJ, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007;67:1842-1852.
Not in our library10.1158/0008-5472.can-06-4038
406.
Sharma A, et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer. 2012;118:4354-4362.
Not in our library10.1002/cncr.26734
407.
Schoen RE, et al. Randomized, double-blind, placebo-controlled trial of MUC1 peptide vaccine for prevention of recurrent colorectal adenoma. Clin. Cancer Res. 2023;29:1678-1688.
Not in our library10.1158/1078-0432.ccr-22-3168
408.
Ebben JD, et al. Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer. Mol. Carcinog. 2016;55:1517-1525.
Not in our library10.1002/mc.22405
409.
Pan J, et al. Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine. Oncotarget. 2017;8:82689-82699.
Not in our library10.18632/oncotarget.19831
410.
Nasti TH, et al. Immunoprevention of chemical carcinogenesis through early recognition of oncogene mutations. J. Immunol. 2015;194:2683-2695.
Not in our library10.4049/jimmunol.1402125
411.
Cunningham TJ, et al. Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. J. Clin. Invest. 2017;127:106-116.
Not in our library10.1172/jci89820
412.
Rosenberg AR, et al. Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. JCI Insight. 2019;4:e125476.
Not in our library10.1172/jci.insight.125476
413.
Centuori SM, Caulin C, Bauman JE. Precision and Immunoprevention Strategies for Tobacco-Related Head and Neck Cancer Chemoprevention. Curr. Treat. Options Oncol. 2021;22:52.
Not in our library10.1007/s11864-021-00848-x
414.
Sun L, et al. Single-cell and spatial dissection of precancerous lesions underlying the initiation process of oral squamous cell carcinoma. Cell Discov. 2023;9:28.
Not in our library10.1038/s41421-023-00532-4
415.
Krysan K, et al. The immune contexture associates with the genomic landscape in lung adenomatous premalignancy. Cancer Res. 2019;79:5022-5033.
Not in our library10.1158/0008-5472.can-19-0153
416.
Hanna GJ, et al. Nivolumab for patients with high-risk oral leukoplakia: A nonrandomized controlled trial. JAMA Oncol. 2024;10:32-41.
Not in our library10.1001/jamaoncol.2023.4853
417.
Steck SE, Murphy EA. Dietary patterns and cancer risk. Nat. Rev. Cancer. 2020;20:125-138.
Not in our library10.1038/s41568-019-0227-4
418.
World Cancer Research Fund International. Diet, nutrition, physical activity and cancer: a global perspective: a summary of the third expert report. Report No. 191225946X, (World Cancer Research Fund International, 2018).
Not in our library
419.
World Cancer Research Fund/American Institute for Cancer Research. Continuous update project expert report 2018. (2018).
Not in our library
420.
Gapstur SM, et al. A blueprint for the primary prevention of cancer: Targeting established, modifiable risk factors. Ca. Cancer J. Clin. 2018;68:446-470.
Not in our library10.3322/caac.21496
421.
Montégut L, de Cabo R, Zitvogel L, Kroemer G. Science-driven nutritional interventions for the prevention and treatment of cancer. Cancer Discov. 2022;12:2258-2279.
Not in our library10.1158/2159-8290.cd-22-0504
422.
Blaževitš O, Di Tano M, Longo VD. Fasting and fasting mimicking diets in cancer prevention and therapy. Trends Cancer. 2023;9:212-222.
Not in our library10.1016/j.trecan.2022.12.006
423.
Khodabakhshi A, et al. Effects of Ketogenic metabolic therapy on patients with breast cancer: A randomized controlled clinical trial. Clin. Nutr. 2021;40:751-758.
Not in our library10.1016/j.clnu.2020.06.028
424.
Khodabakhshi A, et al. Feasibility, safety, and beneficial effects of MCT-based ketogenic diet for breast cancer treatment: A randomized controlled trial study. Nutr. Cancer. 2020;72:627-634.
Not in our library10.1080/01635581.2019.1650942
425.
Klement RJ, Weigel MM, Sweeney RA. A ketogenic diet consumed during radiotherapy improves several aspects of quality of life and metabolic health in women with breast cancer. Clin. Nutr. 2021;40:4267-4274.
Not in our library10.1016/j.clnu.2021.01.023
426.
Dmitrieva-Posocco O, et al. β-Hydroxybutyrate suppresses colorectal cancer. Nature. 2022;605:160-165.
Not in our library10.1038/s41586-022-04649-6
427.
Queen J, Shaikh F, Sears CL. Understanding the mechanisms and translational implications of the microbiome for cancer therapy innovation. Nat. Cancer. 2023;4:1083-1094.
Not in our library10.1038/s43018-023-00602-2
428.
Yang JJ, et al. Association of dietary fiber and yogurt consumption with lung cancer risk: A pooled analysis. JAMA Oncol. 2020;6:e194107.
Not in our library10.1001/jamaoncol.2019.4107
429.
Yu EYW, et al. Grain and dietary fiber intake and bladder cancer risk: a pooled analysis of prospective cohort studies. Am. J. Clin. Nutr. 2020;112:1252-1266.
Not in our library10.1093/ajcn/nqaa215
430.
Arayici ME, et al. Soluble and insoluble dietary fiber consumption and colorectal cancer risk: A systematic review and meta-analysis. Nutr. Cancer. 2021;74:2412-2425.
Not in our library10.1080/01635581.2021.2008990
431.
Yang W, et al. Association of intake of whole grains and dietary fiber with risk of hepatocellular carcinoma in US adults. JAMA Oncol. 2019;5:879-886.
Not in our library10.1001/jamaoncol.2018.7159
432.
Zheng B, et al. Dietary fiber intake and reduced risk of ovarian cancer: a meta-analysis. Nutr. J. 2018;17:99.
Not in our library10.1186/s12937-018-0407-1
433.
Nucci D, et al. Dietary fiber intake and risk of pancreatic cancer: Systematic review and meta-analysis of observational studies. Int. J. Environ. Res. Public Health. 2021;18:11556.
Not in our library10.3390/ijerph182111556
434.
Desai MS, et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell. 2016;167:1339-1353.e1321.
Not in our library10.1016/j.cell.2016.10.043
435.
Schroeder BO, et al. Bifidobacteria or fiber protects against diet-induced microbiota-mediated colonic mucus deterioration. Cell Host Microbe. 2018;23:27-40.e27.
Not in our library10.1016/j.chom.2017.11.004
436.
Makki K, Deehan EC, Walter J, Bäckhed F. The impact of dietary fiber on gut microbiota in host health and disease. Cell Host Microbe. 2018;23:705-715.
Not in our library10.1016/j.chom.2018.05.012
437.
David LA, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505:559-563.
Not in our library10.1038/nature12820
438.
Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised cross-over trial · 2019
No notice
439.
Zhang X, et al. Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial. EBioMedicine. 2023;98:104873.
Not in our library10.1016/j.ebiom.2023.104873
440.
Yang J, et al. High soluble fiber promotes colorectal tumorigenesis through modulating gut microbiota and metabolites in mice. Gastroenterology. 2024;166:323-337.e327.
Not in our library10.1053/j.gastro.2023.10.012
441.
Song M, et al. Effect of supplementation with marine ω-3 fatty acid on risk of colorectal adenomas and serrated polyps in the US general population: A prespecified ancillary study of a randomized clinical trial. JAMA Oncol. 2020;6:108-115.
Not in our library10.1001/jamaoncol.2019.4587
442.
Chen Y-X, et al. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. Lancet Gastroenterol. Hepatol. 2020;5:267-275.
Not in our library10.1016/s2468-1253(19)30409-1
443.
Abdellatif M, Sedej S, Kroemer G. NAD+ metabolism in cardiac health, aging, and disease. Circulation. 2021;144:1795-1817.
Not in our library10.1161/circulationaha.121.056589
444.
Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat. Rev. Mol. Cell Biol. 2021;22:119-141.
Not in our library10.1038/s41580-020-00313-x
445.
Chen AC, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N. Engl. J. Med. 2015;373:1618-1626.
Not in our library10.1056/nejmoa1506197
446.
Allen NC, et al. Nicotinamide for skin-cancer chemoprevention in transplant recipients. N. Engl. J. Med. 2023;388:804-812.
Not in our library10.1056/nejmoa2203086
447.
Carneiro RV, et al. Acitretin and skin cancer in kidney transplanted patients. Clinical and histological evaluation and immunohistochemical analysis of lymphocytes, natural killer cells and Langerhans’ cells in sun exposed and sun protected skin. Clin. Transpl. 2005;19:115-121.
Not in our library10.1111/j.1399-0012.2004.00311.x
448.
Peila R, et al. A randomized trial of calcium plus vitamin d supplementation and risk of ductal carcinoma in situ of the breast. JNCI Cancer Spectr. 2021;5:pkab072.
Not in our library10.1093/jncics/pkab072
449.
Jaszewski R, et al. Folic acid supplementation inhibits recurrence of colorectal adenomas: a randomized chemoprevention trial. World J. Gastroenterol. 2008;14:4492-4498.
Not in our library10.3748/wjg.14.4492
450.
Mocellin S, Briarava M, Pilati P. Vitamin B6 and cancer risk: A field synopsis and meta-analysis. J. Natl Cancer Inst. 2017;109:1-9.
Not in our library10.1093/jnci/djw230
451.
Villagran M, Ferreira J, Martorell M, Mardones L. The role of vitamin C in cancer prevention and therapy: A literature review. Antioxid. (Basel). 2021;10:1894.
Not in our library10.3390/antiox10121894
452.
Dang M, et al. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell. 2023;41:1032-1047.e1034.
Not in our library10.1016/j.ccell.2023.05.007
453.
Baysoy A, Bai Z, Satija R, Fan R. The technological landscape and applications of single-cell multi-omics. Nat. Rev. Mol. Cell. Biol. 2023;24:695-713.
Not in our library10.1038/s41580-023-00615-w
454.
Nishimura T, et al. Evolutionary histories of breast cancer and related clones. Nature. 2023;620:607-614.
Not in our library10.1038/s41586-023-06333-9
455.
Chen Z, Lau KS. Advances in mapping tumor progression from precancer atlases. Cancer Prev. Res. 2023;16:439-447.
Not in our library10.1158/1940-6207.capr-22-0473
456.
Yao P, et al. Protein-level mutant p53 reporters identify druggable rare precancerous clones in noncancerous tissues. Nat. Cancer. 2023;4:1176-1192.
Not in our library10.1038/s43018-023-00608-w
457.
Papaemmanuil E, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616-3627.
Not in our library10.1182/blood-2013-08-518886
458.
Kulasekararaj AG, et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood. 2014;124:2698-2704.
Not in our library10.1182/blood-2014-05-574889
459.
Cancer Genome Atlas Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature507, 315–322 (2012).
Not in our library10.1038/nature12965
460.
Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma · 2019
Corrected
461.
Martincorena I, et al. Somatic mutant clones colonize the human esophagus with age. Science. 2018;362:911-917.
Not in our library10.1126/science.aau3879
462.
Liu X, et al. Genetic alterations in esophageal tissues from squamous dysplasia to carcinoma. Gastroenterology. 2017;153:166-177.
Not in our library10.1053/j.gastro.2017.03.033
463.
Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing · 2017
No notice
464.
Paulson TG, et al. Somatic whole genome dynamics of precancer in Barrett’s esophagus reveals features associated with disease progression. Nat. Commun. 2022;13:2300.
Not in our library10.1038/s41467-022-29767-7
465.
Abbas S, et al. Mutational signature dynamics shaping the evolution of oesophageal adenocarcinoma. Nat. Commun. 2023;14:4239.
Not in our library10.1038/s41467-023-39957-6
466.
Lac V, et al. Oncogenic mutations in histologically normal endometrium: the new normal? J. Pathol. 2019;249:173-181.
Not in our library10.1002/path.5314
467.
Moore L, et al. The mutational landscape of normal human endometrial epithelium. Nature. 2020;580:640-646.
Not in our library10.1038/s41586-020-2214-z
468.
Suda K, et al. Clonal expansion and diversification of cancer-associated mutations in endometriosis and normal endometrium. Cell Rep. 2018;24:1777-1789.
Not in our library10.1016/j.celrep.2018.07.037
469.
Yamaguchi M, et al. Spatiotemporal dynamics of clonal selection and diversification in normal endometrial epithelium. Nat. Commun. 2022;13:943.
Not in our library10.1038/s41467-022-28568-2
470.
Li L, et al. Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma. J. Pathol. 2021;253:119-128.
Not in our library10.1002/path.5566
471.
Nault JC, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat. Commun. 2013;4:2218.
Not in our library10.1038/ncomms3218
472.
Ng SWK, et al. Convergent somatic mutations in metabolism genes in chronic liver disease. Nature. 2021;598:473-478.
Not in our library10.1038/s41586-021-03974-6
473.
Nault JC, et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology. 2014;60:1983-1992.
Not in our library10.1002/hep.27372
474.
Pickering CR, et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin. Cancer Res. 2014;20:6582-6592.
Not in our library10.1158/1078-0432.ccr-14-1768
475.
Fowler JC, et al. Selection of oncogenic mutant clones in normal human skin varies with body site. Cancer Discov. 2021;11:340-361.
Not in our library10.1158/2159-8290.cd-20-1092
476.
Thomson J, et al. The genomic landscape of actinic keratosis. J. Invest. Dermatol. 2021;141:1664-1674.e1667.
Not in our library10.1016/j.jid.2020.12.024
477.
Tang J, et al. The genomic landscapes of individual melanocytes from human skin. Nature. 2020;586:600-605.
Not in our library10.1038/s41586-020-2785-8
478.
Cai Z, et al. Inhibition of inflammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis. Cell. Stem Cell. 2018;23:833-849.e835.
Not in our library10.1016/j.stem.2018.10.013
479.
Meisel M, et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature. 2018;557:580-584.
Not in our library10.1038/s41586-018-0125-z
480.
Higa KC, et al. Chronic interleukin-1 exposure triggers selection for Cebpa-knockout multipotent hematopoietic progenitors. J. Exp. Med. 2021;218:e20200560.
Not in our library10.1084/jem.20200560
481.
Somatic Evolution in Non-neoplastic IBD-Affected Colon · 2020
No notice
482.
Sun X, et al. Suppression of the SWI/SNF component Arid1a promotes mammalian regeneration. Cell. Stem Cell. 2016;18:456-466.
Not in our library10.1016/j.stem.2016.03.001
483.
Zhu L, et al. Multi-organ mapping of cancer risk. Cell. 2016;166:1132-1146.e1137.
Not in our library10.1016/j.cell.2016.07.045
484.
Sato N, et al. The COX-2/PGE(2) pathway suppresses apical elimination of RasV12-transformed cells from epithelia. Commun. Biol. 2020;3:132.
Not in our library10.1038/s42003-020-0847-y
485.
Dawoud AAZ, Tapper WJ, Cross NCP. Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking. Leukemia. 2020;34:2660-2672.
Not in our library10.1038/s41375-020-0896-8
486.
Wong TN, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015;518:552-555.
Not in our library10.1038/nature13968
487.
Murai K, et al. Epidermal tissue adapts to restrain progenitors carrying clonal p53 mutations. Cell. Stem Cell. 2018;23:687-699.e688.
Not in our library10.1016/j.stem.2018.08.017
488.
Moon H, et al. Melanocyte stem cell activation and translocation initiate cutaneous melanoma in response to UV exposure. Cell. Stem Cell. 2017;21:665-678.e666.
Not in our library10.1016/j.stem.2017.09.001
489.
Viros A, et al. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53. Nature. 2014;511:478-482.
Not in our library10.1038/nature13298
490.
Bruens L, et al. Calorie restriction increases the number of competing stem cells and decreases mutation retention in the intestine. Cell Rep. 2020;32:107937.
Not in our library10.1016/j.celrep.2020.107937
491.
Cai Z, et al. Hyperglycemia cooperates with Tet2 heterozygosity to induce leukemia driven by proinflammatory cytokine-induced lncRNA Morrbid. J. Clin. Invest. 2021;131:e140707.
Not in our library10.1172/jci140707
492.
Liang S, et al. Gut microbiome associated with APC gene mutation in patients with intestinal adenomatous polyps. Int. J. Biol. Sci. 2020;16:135-146.
Not in our library10.7150/ijbs.37399
493.
Belote RL, et al. Human melanocyte development and melanoma dedifferentiation at single-cell resolution. Nat. Cell Biol. 2021;23:1035-1047.
Not in our library10.1038/s41556-021-00740-8
494.
Nowicki-Osuch K, et al. Molecular phenotyping reveals the identity of Barrett’s esophagus and its malignant transition. Science. 2021;373:760-767.
Not in our library10.1126/science.abd1449
495.
Delineating the dynamic evolution from preneoplasia to invasive lung adenocarcinoma by integrating single-cell RNA sequencing and spatial transcriptomics · 2022
No notice
496.
Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity · 2022
No notice
497.
Wang R, et al. Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression. Cancer Cell. 2023;41:1407-1426.e1409.
Not in our library10.1016/j.ccell.2023.06.005
498.
Gil Del Alcazar CR, et al. Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discov. 2017;7:1098-1115.
Not in our library10.1158/2159-8290.cd-17-0222
499.
Zavidij O, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat. Cancer. 2020;1:493-506.
Not in our library10.1038/s43018-020-0053-3
500.
Co-evolution of tumor and immune cells during progression of multiple myeloma · 2021
No notice
501.
Carpenter ES, et al. Analysis of donor pancreata defines the transcriptomic signature and microenvironment of early neoplastic lesions. Cancer Discov. 2023;13:1324-1345.
Not in our library10.1158/2159-8290.cd-23-0013
502.
Liu X, et al. Spatial transcriptomics analysis of esophageal squamous precancerous lesions and their progression to esophageal cancer. Nat. Commun. 2023;14:4779.
Not in our library10.1038/s41467-023-40343-5
503.
Lee SH, et al. Apposition of fibroblasts with metaplastic gastric cells promotes dysplastic transition. Gastroenterology. 2023;165:374-390.
Not in our library10.1053/j.gastro.2023.04.038
504.
Bernard V, et al. Single-cell transcriptomics of pancreatic cancer precursors demonstrates epithelial and microenvironmental heterogeneity as an early event in neoplastic progression. Clin. Cancer Res. 2019;25:2194-2205.
Not in our library10.1158/1078-0432.ccr-18-1955
505.
Schütz S, et al. Functionally distinct cancer-associated fibroblast subpopulations establish a tumor promoting environment in squamous cell carcinoma. Nat. Commun. 2023;14:5413.
Not in our library10.1038/s41467-023-41141-9
506.
Widlak MM, et al. Risk stratification of symptomatic patients suspected of colorectal cancer using faecal and urinary markers. Colorectal Dis. 2018;20:O335-O342.
Not in our library10.1111/codi.14431
507.
Wong SH, et al. Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia. Gut. 2017;66:1441-1448.
Not in our library10.1136/gutjnl-2016-312766
508.
Uchiyama K, et al. Serum metabolomics analysis for early detection of colorectal cancer. J. Gastroenterol. 2017;52:677-694.
Not in our library10.1007/s00535-016-1261-6
509.
Le Cornet C, et al. Circulating immune cell composition and cancer risk: A prospective study using epigenetic cell count measures. Cancer Res. 2020;80:1885-1892.
Not in our library10.1158/0008-5472.can-19-3178
510.
Yamashita S, et al. Genetic and epigenetic alterations in normal tissues have differential impacts on cancer risk among tissues. Proc. Natl. Acad. Sci. Usa. 2018;115:1328-1333.
Not in our library10.1073/pnas.1717340115
511.
Ho PJ, et al. Breast cancer risk stratification using genetic and non-genetic risk assessment tools for 246,142 women in the UK Biobank. Genet. Med. 2023;25:100917.
Not in our library10.1016/j.gim.2023.100917
512.
Jobard E, et al. Investigation of circulating metabolites associated with breast cancer risk by untargeted metabolomics: a case-control study nested within the French E3N cohort. Br. J. Cancer. 2021;124:1734-1743.
Not in our library10.1038/s41416-021-01304-1
513.
Sin DD, et al. Pro-surfactant protein B as a biomarker for lung cancer prediction. J. Clin. Oncol. 2013;31:4536-4543.
Not in our library10.1200/jco.2013.50.6105
514.
Guida F, et al. Assessment of lung cancer risk on the basis of a biomarker panel of circulating proteins. JAMA Oncol. 2018;4:e182078.
Not in our library10.1001/jamaoncol.2018.2078
515.
Beane J, et al. Detecting the presence and progression of premalignant lung lesions via airway gene expression. Clin. Cancer Res. 2017;23:5091-5100.
Not in our library10.1158/1078-0432.ccr-16-2540
516.
Huang RJ, et al. Pepsinogens and gastrin demonstrate low discrimination for gastric precancerous lesions in a multi-ethnic United States cohort. Clin. Gastroenterol. Hepatol. 2022;20:950-952.e953.
Not in our library10.1016/j.cgh.2021.01.009
517.
Zagari RM, et al. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment. Pharmacol. Ther. 2017;46:657-667.
Not in our library10.1111/apt.14248
518.
Li, X. et al. Proteomic profiling identifies signatures associated with progression of precancerous gastric lesions and risk of early gastric cancer. EBioMedicine74, 103714 (2021).
Not in our library10.1016/j.ebiom.2021.103714
519.
Verhoef VM, et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol. 2014;15:315-322.
Not in our library10.1016/s1470-2045(14)70019-1
520.
Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation · 2012
No notice
521.
Wu Z, et al. Development of models for cervical cancer screening: construction in a cross-sectional population and validation in two screening cohorts in China. BMC Med. 2021;19:197.
Not in our library10.1186/s12916-021-02078-2
522.
Shaw VE, et al. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Mol. Cancer. 2014;13:114.
Not in our library10.1186/1476-4598-13-114
523.
Colbert K, et al. Molecular cancer prevention: Current status and future directions. CA Cancer J. Clin. 2015;65:345-383.
Not in our library10.3322/caac.21287
524.
Rothwell PM, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741-1750.
Not in our library10.1016/s0140-6736(10)61543-7
525.
Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial · 2018
No notice
526.
Takayama T, et al. Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps. Clin. Cancer Res. 2011;17:3803-3811.
Not in our library10.1158/1078-0432.ccr-10-2395
527.
Bertagnolli MM, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 2006;355:873-884.
Not in our library10.1056/nejmoa061355
528.
Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial. · 2014
Not checked
529.
Bavinck JN, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J. Clin. Oncol. 1995;13:1933-1938.
Not in our library10.1200/jco.1995.13.8.1933
530.
Chen AC, et al. A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. Br. J. Dermatol. 2016;175:1073-1075.
Not in our library10.1111/bjd.14662
531.
Barry EL, et al. Vitamin D receptor genotype, vitamin D3 supplementation, and risk of colorectal adenomas: A randomized clinical trial. JAMA Oncol. 2017;3:628-635.
Not in our library10.1001/jamaoncol.2016.5917
532.
Baron JA, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N. Engl. J. Med. 1999;340:101-107.
Not in our library10.1056/nejm199901143400204
533.
Reid ME, et al. Selenium supplementation and colorectal adenomas: An analysis of the nutritional prevention of cancer trial. Int. J. Cancer. 2006;118:1777-1781.
Not in our library10.1002/ijc.21529

Cited by papers we hold 2

Lung Cancer—Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature) · 2025
No notice
Free radicals and their impact on health and antioxidant defenses: a review · 2025
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.